Weekly Paclitaxel Infusion as Salvage Therapy in Ovarian Cancer

摘要: The majority of women diagnosed with epithelial ovarian cancer will have persistent or recurrent disease after initial treatment. We evaluated response and toxicity in advanced stage given salvage paclitaxel as a low-dose, weekly infusion. performed retrospective review 22 (19 women) primary peritoneal carcinoma (3 who had received therapy. All refractory, persistent, following first-line treatment platin chemotherapy. Response were assessed. Measurable present on physical radiologic exam serum carbohydrate antigen-125 levels used to assess response. Overall rate therapy was 50% (27% complete, 23% partial). Median progression-free interval (PFI) responders 27 weeks (range, 14-68 weeks). Stabilization occurred an additional 27% patients median PFI 15-89 No difference detected between the 7 platin-sensitive 15 platin-resistant (P = 0.19). dose 80 mg/m2 60-80 mg/m2). During total 325 (median per patient, 12 weeks; range, 6-49 weeks), 13 delays (hematologic indication, 9; nonhematologic 4). cases grade 4 hematologic toxicity, sepsis, worsening neuropathy documented. Weekly infusion results significant clinical response, even previously treated paclitaxel. regimen is well tolerated no neutropenia our population.